Hepatitis C Enrollment Form Medications A-L



(Epclusa, Harvoni, Ledipasvir/Sofosbuvir)

Fax Referral To: 1-888-280-1191 OR 787-759-4161 Phone: 1-888-280-1190 OR 787-759-4162

CVS specialty ° Email Referral To: Customer.ServiceFax@CVSHealth.com Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927 Six Simple Steps to Submitting a Referral PATIENT INFORMATION (Complete or include demographic sheet) Patient Name: Address: City, State, ZIP Code: Gender: Male Female Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. Alternate Phone: If Minor, Parent/Caregiver/Guardian Name (Last, First): Relationship to minor: Last Four of SSN: Primary Language: Email: 2 PRESCRIBER INFORMATION Prescriber's Name: ___ _____ State License #: _____ NPI #: _____ DEA #: _____ Group or Hospital: _____ Address: _____ __ City, State, ZIP Code: _____ _____Fax_____Contact Person: ______Contact's Phone: _____ Phone: INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) 4 DIAGNOSIS AND CLINICAL INFORMATION ______ Ship to: Patient Office Other: ____ Needs by Date: Diagnosis (ICD-10): B17.10 Acute Hepatitis C without hepatic coma B17.11 Acute Hepatitis C with hepatic coma B19.20 Unspecified Viral Hepatitis C without hepatic coma B18.2 Chronic Hepatitis C Other Code: _____ Description ___ B20 HIV **Patient Clinical Information:** Height: ____in/cm Alleraies: _ Weight: ____lb/kg HCV Genotype: 1a 1b 1 2 3 4 5 6 AND No Cirrhosis Compensated Cirrhosis Decompensated Cirrhosis Is patient: Naïve Partial Responder Non-Responder Relapser; Last Date of Therapy: _____ Product Name(s): _____ Is patient currently on Hepatitis C Virus therapy? No Yes, Therapy Start Date: Product Name(s): _____ Specialty pharmacy to coordinate injection training/home health nurse visit as necessary? Tyes No Site of Care: MD office Infusion Clinic Outpatient Health Home Health Injection training not necessary. Date training occurred: Reason: MD office training patient Pt already independent Referred by MD to alternate trainer 5 PRESCRIPTION INFORMATION **MEDICATION** STRENGTH **DOSE & DIRECTIONS QUANTITY/REFILLS** Fixed-dose combination tablet of Quantity: _____ Epclusa 400 mg sofosbuvir / 100 mg Take one tablet once daily. Refills: ____ (sofosbuvir / velpatasvir) velpatasvir Quantity: 28-day supply Fixed-dose combination tablet of Take PO once daily with or without Refills: Harvoni 90 mg ledipasvir / 400 mg food. Do not take within 4 hours of 8 weeks (ledipasvir/sofosbuvir) sofosbuvir antacids. 12 weeks 24 weeks Quantity: 28-day supply Fixed-dose combination tablet of Take PO once daily with or without Refills: food. Do not take within 4 hours of 8 weeks Ledipasvir/ Sofosbuvir 90 mg ledipasvir / 400 mg 12 weeks sofosbuvir antacids. 24 weeks

STAMP SIGNATURE NOT ALLOWED ☐ Patient is interested in patient support programs Ancillary supplies and kits provided as needed for administration 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / May Substitute / Product Selection Permitted /

DAW / May Not Substitute Prescriber's Signature: Substitution Permissible

Prescriber's Signature: CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ______ ATTN: New York and Iowa providers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication

Medications M-S Hepatitis C Enrollment Form

(Mavyret, Pegasys, Pegintron, Ribavirin, Ribasphere RibaPak, Sofosbuvir/Velpatasvir, Sovaldi)

atient Name:		Pa	atient DOB:				
rescriber Name:		Pr	escriber Phone:				
PRESCRIPTION INFORMATION							
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS			
Mavyret Tablet (glecaprevir and pibrentasvir)	Fixed-dose combination tablet of 100 mg glecaprevir and 40 mg pibrentasvir	Take ti	nree tablets PO once a day with food.	Quantity: 28-day supply Refills: 8 weeks 12 weeks Other			
Mavyret Oral Pellet (glecaprevir and pibrentasvir)	Fixed-dose combination oral pellet of 50 mg glecaprevir and 20 mg pibrentasvir	kg/lb Take three packets of oral pellets PO once daily with food. Take four packets of oral pellets PO once daily with food. Take five packets of oral pellets PO once daily with food.		Quantity: 28-day supply Refills: 8 weeks 12 weeks Other			
Pegasys (peginterferon alfa-2a)	☐ 180 mcg / 0.5 mL ProClick Autoinjector ☐ Other:	☐ Inject 180 mcg SC once a week as directed. ☐ Other:		Quantity: Refills:			
Pegintron (peginterferon alfa-2b)	☐ 120 mcg REDIPEN ☐ 150 mcg REDIPEN ☐ Other:	☐ Inject mcg SC weekly. ☐ Other:		Quantity: Refills:			
Ribavirin	200 mg tablets 200 mg capsules	Take tabs/caps PO q am and tabs/caps q pm for a total of mg daily with food.		Quantity: Refills:			
Ribasphere RibaPak (ribavirin)	☐ 600 / 600 mg ☐ 600 / 400 mg ☐ 400 / 400 mg ☐ 200 / 400 mg	Take mg PO q am and mg q pm for a total of mg daily with food.		Quantity: Refills:			
Sofosbuvir/ /elpatasvir	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir	Take one tablet once daily.		Quantity: Refills:			
Sovaldi (sofosbuvir)	400 mg tablets	Take one 400 mg tablet PO once a day.		Quantity: 28-day supply Refills:			
Patient is interested in patient supp	RIBER SIGNATURE REQUIR			provided as needed for administratio			
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature:			May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	_Date:			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

©2022 CVS Specialty Inc. and one of its affiliates. 75-38495B 02/28/22

Medications M-Z Hepatitis C Enrollment Form

(Technivie, Viekira Pak, Vosevi, Zepatier)

	<u>Please Complete Patien</u>	t and I	Prescriber Information				
Patient Name:	Patient DOB:						
	Prescriber Phone:						
PRESCRIPTION IN	IFORMATION						
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS			
Technivie (ombitasvir/paritaprevir /ritonavir)	Fixed dose combination tablet of ombitasvir / paritaprevir / ritonavir 12.5 mg / 75 mg / 50 mg	Take two tablets once daily in the morning.		Quantity: 28-day supply Refills:12 weeks			
Viekira Pak (ombitasvir/paritaprevir /ritonavir tabs and dasabuvir tabs)	Copackaged ombitasvir / partiaprevir / ritonavir 12.5 mg / 75 mg / 50 mg and dasabuvir 250 mg	Take 2 pink tablets (ombitasvir, paritaprevir, ritonavir) once daily (morning) and 1 beige tablet (dasabuvir) twice daily (morning and evening) with meals.		Quantity: 28-day supply Refills: 12 weeks 24 weeks			
☐ Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir/100 mg voxilaprevir	Take one tablet PO once a day with food.		Quantity: 28-day supply Refills: 12 weeks Other			
Zepatier (elbasvir/grazoprevir)	Fixed dose combination tablet of 50 mg elbasvir / 100 mg grazoprevir	Take one tablet once daily with or without food.		Quantity: 28-day supply Refills: 12 weeks 16 weeks			
Patient is interested in patient supp	. •			provided as needed for administration			
<u>o</u> PRE	SCRIBER SIGNATURE REQUIRE	יס (5 ו	AMP SIGNATURE NOT ALLO	WED)			
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No S DAW / May Not Substitute			May Substitute / Product Selection Permitted / Substitution Permissible				
Prescriber's Signature:	Date:		Prescriber's Signature:	Date:			
CA. MA. NC & PR: Interchange is a	mandated unless Prescriber writes the words "No Substitu	ıtion"	ATTN: New York and lowe provide	ers nlease submit electronic prescri			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2022 CVS Specialty Inc. and one of its affiliates. 75-38495B 02/28/22